These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 24695949)

  • 1. Sustained pro-haemostatic activity of rFVIIa in plasma and platelets in non-bleeding pigs may explain the efficacy of a once-daily prophylaxis in humans.
    Schut AM; Hyseni A; Adelmeijer J; Meijers JC; De Groot PG; Lisman T
    Thromb Haemost; 2014 Aug; 112(2):304-10. PubMed ID: 24695949
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prolonged effect of GlycoPEGylated rFVIIa (40k-PEG-rFVIIa) in rabbits correlates to activity in plasma.
    Johansen PB; Bjørn SE; Agersø H; Thorup I; Hermit MB; Sørensen B; Stennicke HR; Ezban M; Tranholm M
    Thromb Haemost; 2010 Jul; 104(1):157-64. PubMed ID: 20390231
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Platelet-dependent thrombin generation assay for monitoring the efficacy of recombinant Factor VIIa.
    Wegert W; Harder S; Bassus S; Kirchmaier CM
    Platelets; 2005 Feb; 16(1):45-50. PubMed ID: 15763896
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel therapeutic approach combining human plasma-derived Factors VIIa and X for haemophiliacs with inhibitors: evidence of a higher thrombin generation rate in vitro and more sustained haemostatic activity in vivo than obtained with Factor VIIa alone.
    Tomokiyo K; Nakatomi Y; Araki T; Teshima K; Nakano H; Nakagaki T; Miyamoto S; Funatsu A; Iwanaga S
    Vox Sang; 2003 Nov; 85(4):290-9. PubMed ID: 14633255
    [TBL] [Abstract][Full Text] [Related]  

  • 5. First 20 years with recombinant FVIIa (NovoSeven).
    Hedner U; Lee CA
    Haemophilia; 2011 Jan; 17(1):e172-82. PubMed ID: 20609014
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monitoring rFVIIa 90 μg kg⁻¹ dosing in haemophiliacs: comparing laboratory response using various whole blood assays over 6 h.
    Brophy DF; Martin EJ; Christian Barrett J; Nolte ME; Kuhn JG; Gerk PM; Carr ME; Pelzer H; Agersø H; Ezban M; Hedner U
    Haemophilia; 2011 Sep; 17(5):e949-57. PubMed ID: 21362113
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bio-distribution of pharmacologically administered recombinant factor VIIa (rFVIIa).
    Gopalakrishnan R; Hedner U; Ghosh S; Nayak RC; Allen TC; Pendurthi UR; Rao LV
    J Thromb Haemost; 2010 Feb; 8(2):301-10. PubMed ID: 19943873
    [TBL] [Abstract][Full Text] [Related]  

  • 8. General haemostatic agents--fact or fiction?
    Hedner U
    Pathophysiol Haemost Thromb; 2002; 32 Suppl 1():33-6. PubMed ID: 12214145
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Variability of thromboelastographic responses following the administration of rFVIIa to haemophilia A dogs supports the individualization of therapy with a global test of haemostasis.
    Othman M; Powell S; Hopman WM; Lillicrap D
    Haemophilia; 2010 Nov; 16(6):919-25. PubMed ID: 20609015
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Understanding the therapeutic action of recombinant factor VIIa in platelet disorders.
    Hers I; Mumford A
    Platelets; 2008 Dec; 19(8):571-81. PubMed ID: 19012175
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factor VIIa and its potential therapeutic use in bleeding-associated pathologies.
    Hedner U
    Thromb Haemost; 2008 Oct; 100(4):557-62. PubMed ID: 18841276
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recombinant factor VIIa partially reverses the inhibitory effect of fondaparinux on thrombin generation after tissue factor activation in platelet rich plasma and whole blood.
    Gerotziafas GT; Depasse F; Chakroun T; Samama MM; Elalamy I
    Thromb Haemost; 2004 Mar; 91(3):531-7. PubMed ID: 14983229
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety, pharmacokinetics and efficacy of factor VIIa formulated with PEGylated liposomes in haemophilia A patients with inhibitors to factor VIII--an open label, exploratory, cross-over, phase I/II study.
    Spira J; Plyushch O; Zozulya N; Yatuv R; Dayan I; Bleicher A; Robinson M; Baru M
    Haemophilia; 2010 Nov; 16(6):910-8. PubMed ID: 20491957
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Manipulation of prothrombin concentration improves response to high-dose factor VIIa in a cell-based model of haemophilia.
    Allen GA; Hoffman M; Roberts HR; Monroe DM
    Br J Haematol; 2006 Aug; 134(3):314-9. PubMed ID: 16787497
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and safety of a 270 mcg kg-1 dose of room temperature stable recombinant activated factor VII in patients with haemophilia.
    Morfini M; Bjerre J
    Haemophilia; 2011 Nov; 17(6):860-6. PubMed ID: 21371194
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The pharmacokinetics and pharmacodynamics of single-dose and multiple-dose recombinant activated factor VII in patients with haemophilia A or B.
    Fernández-Bello I; Stenmo C; Butta N; Lind V; Ezban M; Jiménez-Yuste V
    Haemophilia; 2017 Nov; 23(6):868-876. PubMed ID: 28851065
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of platelets and recombinant factor VIIa on thrombin generation, platelet activation and clot formation.
    Gerotziafas GT; Chakroun T; Depasse F; Arzoglou P; Samama MM; Elalamy I
    Thromb Haemost; 2004 May; 91(5):977-85. PubMed ID: 15116259
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of increasing doses of activated recombinant factor VII on haemostatic parameters in swine.
    Pusateri AE; Ryan KL; Delgado AV; Martinez RS; Uscilowicz JM; Cortez DS; Martinowitz U
    Thromb Haemost; 2005 Feb; 93(2):275-83. PubMed ID: 15711743
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of refractory bleeding after cardiac operations with low-dose recombinant activated factor VII (NovoSeven): a propensity score analysis.
    Gelsomino S; Lorusso R; Romagnoli S; Bevilacqua S; De Cicco G; Billè G; Stefàno P; Gensini GF
    Eur J Cardiothorac Surg; 2008 Jan; 33(1):64-71. PubMed ID: 17996457
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prolonged in-vivo half-life of factor VIIa by fusion to albumin.
    Weimer T; Wormsbächer W; Kronthaler U; Lang W; Liebing U; Schulte S
    Thromb Haemost; 2008 Apr; 99(4):659-67. PubMed ID: 18392323
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.